Compare Recursion Pharmaceuticals Inc (RXRX) vs Zscaler Inc (ZS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Recursion Pharmaceuticals Inc vs Zscaler Inc — how do they compare? Recursion Pharmaceuticals Inc trades at $3.29 (market cap $1.81B), while Zscaler Inc trades at $176.77 (market cap $28.87B). The key difference: Zscaler Inc is far larger — about 16× Recursion Pharmaceuticals Inc's market cap, and Zscaler Inc is trading nearer its 52-week high, Recursion Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.
| RXRX | ZS | |
|---|---|---|
Market Cap | $1.81B | $28.87B |
Sector | Health | Technology |
52-Week High | $6.79 | $336.27 |
52-Week Low | $2.84 | $118.05 |
Enterprise Value | $1.33B | $27.20B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
RXRX trades at $3.295, up 0.15% on the day, with a bullish technical signal from moving averages but mixed oscillators. The company reported a Q2 2026 earnings miss with revenue declining year-over-year, while maintaining a strong cash position from financing activities. Recent news highlights participation in investor conferences and partnership advancements with Genentech.
Outlook remains speculative with high revenue growth potential from AI-driven drug discovery partnerships, but significant risks persist due to deep losses and negative margins. Analyst sentiment is mixed with a 40% buy rating, emphasizing the stock's high-risk, high-reward profile dependent on future clinical and commercial milestones.
Zscaler (ZS) trades at $176.11, showing modest daily movement. The stock exhibits a bullish technical trend with strong analyst support, evidenced by 42 buy ratings and a consensus price target of $191.81. Recent earnings consistently beat expectations, with Q1 2026 EPS of $1.08 surpassing the $1.01 forecast. Revenue growth is robust, increasing from $1.1B in 2022 to $2.67B in 2025, though the company remains unprofitable with a net income margin of -2.44%.
The outlook is positive due to strong revenue growth, leadership in cloud security, and bullish analyst sentiment. Key risks include persistent unprofitability, high valuation multiples like a P/S of 8.94, and competitive pressures in the cybersecurity sector. The upcoming Q2 2026 earnings report on September 3, 2026, will be critical for validating growth trajectory and investor confidence.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →About Zscaler Inc
Zscaler is a security-as-a-service firm that offers its customers cloud-delivered solutions for protecting user devices and data. The firm leverages its position in 150 colocation data centers to deliver traditionally appliance-based security functionality, such as firewalls and sandboxes, as a completely cloud-native platform. The firm focuses on large enterprise customers and offers two primary product suites: Zscaler Internet Access, which securely connects users to externally managed application and websites (such as Salesforce and Google), and Zscaler Private Access, which securely connects users to internally managed applications. Both product suites encompass a broad gamut of capabilities situated across the traditional security stack.
Read more on ZS →
